Primary Biliary Cholangitis

Primary biliary cholangitis (PBC), previously called primary biliary cirrhosis, is a chronic disease in which the bile ducts in the liver are slowly destroyed.

Investigators

Craig Lammert, MD

Assistant Professor of Medicine

Raj Vuppalanchi, MD

Professor of Medicine

Open Research Studies for Primary Biliary Cholangitis

Cara PBC

Enrolling: Yes

Principle Investigator: Raj Vuppalanchi, MD

Duration: 21 weeks

Patient Population: Patients with moderate to severe itching.

Drug(s): Oral CR845

Interested in this study? Please contact the coordinator below:
Mandy Cruz
mandcruz@iu.edu
(317) 278-6215

TRANSFORM: A 52-week, Randomized, Placebo-controlled, Double-blind, Adaptive Phase 2b/3 Trial of Setanaxib with a 52-week Extension Phase in Patients with Primary Biliary Cholangitis (PBC) and Elevated Liver Stiffness

Enrolling: On Hold

Principle Investigator: Raj Vuppalanchi, MD

Duration: 120 weeks

Patient Population: Patients over the age of 18 with a definite or probable diagnosis of PBC.

Drug(s): Setanaxib

Interested in this study? Please contact the coordinator below:
Kelsey Green
greenke@iu.edu

(317) 278-9292

Zydus PBC

Enrolling: Yes

Principle Investigator: Raj Vuppalanchi, MD

Duration: 26 weeks

Patient Population: Non-cirrhotic

Drug(s): Oral Saroglitazar

Interested in this study? Please contact the coordinator below:
Mandy Cruz
mandcruz@iu.edu
(317) 278-6215

Closed Primary Biliary Cholangitis Studies

Intercept 302 - PBC

Enrolling: No
Principle Investigator: Raj Vuppalanchi, MD

Duration: Upwards 6 - 8 years.

Patient Population: PBC with total Bili > ULN and ≤3x ULN or ALP >5x ULN

Drug(s): Obeticholic Acid tablet or placebo
PBC Itch

Enrolling: No

Principle Investigator: Craig Lammert, MD

Duration: 1 visit

Patient Population: PBC/Pre-Transplant and history of no/minimal itch or severe itch.